Clinical trials: Cancer Stem Cells
Hematological Malignancies
Extracorporal Photopheresis Pilot Study
ECP will be given to the patients [UVAR®XTS TM Therakos system, Johnson \& Johnson] according to the following schedule: Starting at day 21 after transplant, if hematologic recovery allowed it: 2 ECP per week the first 2 weeks…
- Trial name
- ECP (NCT00930566)
- Testing
- methoxsalen, Extracoporal Photopheresis (ECP)
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
DIPG Brain Tumor, Diffuse Intrinsic Pontine Glioma
Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.
- Trial name
- CMD03DIPG (NCT06221553)
- Testing
- B7H3 specific CAR T cell with IL-7Ra signaling domain
- Where
- Thailand
- Volunteers
- 9 people
- Sponsor
- Chulalongkorn University
Hematologic Malignancies
Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support
Objectives: 1. To determine the relative toxicities, engraftment potential, kinetics of engraftment, degree of chimerism and disease control achieved with the combination of fludarabine and busulfan at different dose levels and…
- Trial name
- NCT00506857
- Testing
- Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- M.D. Anderson Cancer Center
Bone Marrow Transplantation, Blood Disease
Blood and Marrow Transplant Clinical Research Network
The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones.
- Conditions
- Bone Marrow Transplantation, Blood Disease, Hematopoietic Stem Cell Transplantation, Leukemia
- Trial name
- NCT00023530
- Testing
- fluconazole, voriconazole, bone marrow transplant
- Where
- 16 sites in United States
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Leukemia
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002838
- Testing
- Filgrastim (G-CSF), Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radioactive drugs such as holmium Ho 166 DOTMP can kill cancer cells without harming healthy cells.
- Trial name
- NCT00008229
- Testing
- filgrastim, melphalan, peripheral blood stem cell transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
AML, NHL
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence…
- Conditions
- AML, NHL, Hodgkin Disease, All
- Trial name
- HBO-UBC (NCT03739502)
- Testing
- Hyperbaric oxygen
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Rochester
Multiple Myeloma, Plasma Cell Myeloma
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as thalidomide and lenalidomide, may stimulate the immune system in different ways and…
- Trial name
- NCT01055301
- Testing
- bortezomib, cisplatin, cyclophosphamide
- Where
- 21 sites in United States
- Sponsor
- SWOG Cancer Research Network
Leukemia, Lymphoma
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
The purpose of this study is to determine the safety and toxicity and feasibility of double umbilical cord blood transplantation (DUCBT) in patients with selected malignant and non-malignant, and to quantify the percentage and…
- Conditions
- Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies
- Trial name
- NCT00801931
- Testing
- Alemtuzumab, Total Body Irradiation, Melphalan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
Acute Myeloid Leukemia in Remission
Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT
Relapse remains the main cause of death in patients with myeloid malignancies, especially after an allotransplant. Using drugs with higher anti-leukemic activity as part of the conditioning regimen is one of the strategies to…
- Trial name
- FLUCLORIC (NCT05917405)
- Testing
- Fludarabine, Busulfan, ATG
- Where
- 23 sites in France
- Volunteers
- 302 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma and Plasma Cell Neoplasm
High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
RATIONALE: Giving chemotherapy and bortezomib before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00747877
- Testing
- cyclophosphamide, melphalan, autologous hematopoietic stem cell transplantation
- Where
- 53 sites in United Kingdom
- Volunteers
- 460 people
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital
Paediatric Patients Affected by Haematological Malignancies and Eligible to Undergo HSCT From an Unrelated Volunteer
Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation
Paediatric patients affected by haematological malignancies and eligible to undergo HSCT from an unrelated volunteer will be stratified according to the degree of compatibility with their donor, the source of haematopoietic stem…
- Trial name
- ATG FRES (NCT00934557)
- Testing
- ATG Fresenius
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Neuroblastoma, Brain Tumor
Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
The purpose of this study is to investigate whether the prophylactic use of itraconazole is a better option than empirical use of itraconazole in the management (prevention and treatment) of fungal infection associated with…
- Conditions
- Neuroblastoma, Brain Tumor, Retinoblastoma, Wilms Tumor
- Trial name
- NCT00336531
- Testing
- itraconazole
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
Hematological Disease, Immune Deficiencies
URMC Related Haplo-identical Donor BMT
This study will be a single-center treatment protocol, designed to validate the process of related donor haploidentical-SCT at the Wilmot Cancer Institute Blood and Marrow Transplant Unit.
- Conditions
- Hematological Disease, Immune Deficiencies, Solid Tumors, Myelofibrosis
- Trial name
- HaploOnly (NCT02660281)
- Testing
- Total Body Irradiation 1200 cGy, Fludarabine, Pre-Stem Cell Infusion Cyclophosphamide
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Rochester
Streptococcal Sepsis, Hematologic Malignancies
Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation
This is a randomized 2-arm study to compare two different times of giving the drug vancomycin. Half of the patients will begin vancomycin two days before a bone marrow transplant.
- Trial name
- NCT00138112
- Testing
- Empirical Vancomycin, Prophylactic Vancomycin
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Refractory Multiple Myeloma
Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase I/II trial studies the side effects of giving reduced-intensity conditioning followed by donor peripheral blood stem cell transplant (PBSCT) and how well it works in treating patients with multiple myeloma (MM).
- Trial name
- NCT00054353
- Testing
- fludarabine phosphate, melphalan, total-body irradiation
- Where
- 2 sites in United States, Italy
- Volunteers
- 16 people
- Sponsor
- Fred Hutchinson Cancer Center
Diffuse Intrinsic Pontine Glioma
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
This phase I trial studies the side effects and best dose of temsirolimus when given together with vorinostat and with or without radiation therapy in treating younger patients with newly diagnosed or progressive diffuse…
- Trial name
- NCT02420613
- Testing
- Radiation Therapy, Temsirolimus, Vorinostat
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00941720
- Testing
- busulfan, cyclophosphamide, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Case Comprehensive Cancer Center
Haematologic Disease
Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation
For several decades, allogeneic hematopoietic stem cell trans-plantation (allo-HSCT) has remained an important strategy in the management of patients with high-risk hematological malignancies.
- Trial name
- CTL-DP 01 (NCT04180059)
- Testing
- CTL 19
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Nantes University Hospital
Brain Tumor, Recurrent
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
The goal of this proposal is to evaluate a new Photodynamic Therapy (PDT) modification which could revolutionize the treatment of brain tumors in children and adults.
- Trial name
- NCT01682746
- Testing
- Photofrin (porfimer sodium) & photodynamic therapy.
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Harry T Whelan, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.